Log In or Create Account
Resistance Mutations
Podcasts
Key Slides
Question of the Week
CROI
RWHAP Clinical Conference
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
DEA-Compliant SUD Webinars
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
Did You Know?
FAQs
Fellow/Student Resources
Fellow/Student Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Mission
Scientific Leadership Board
Core Faculty
IAS-USA Award Recipients
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Menu
Topics in Antiviral Medicine
™
April/May 2022
Volume 30, Issue 2
Download here
, or select individual articles
Claim CME
Invited Reviews
CROI 2022: Summary of Basic Science Research in HIV and SARS-CoV-2
Mario Stevenson, PhD
CROI 2022: Epidemiologic Trends and Prevention for HIV and SARS-CoV-2
Susan Buchbinder, MD, Albert Liu, MD, MPH
Addressing Depressive Disorders Among People With HIV
Andres Fuenmayor, MD, Francine Cournos, MD
Update on Tuberculosis/HIV Coinfections: Across the Spectrum From Latent Infection Through Drug- Susceptible and Drug-Resistant Disease
Elisa H. Ignatius, MD, MSc, Susan Swindells, MBBS
Topics in Antiviral Medicine™
Current Issues
Previous Issues
TAM
Policies and Practices
TAM
Author and Contributor Guidelines
Topics in Antiviral Medicine
Editorial Board
Resistance Mutations
Podcasts
Key Slides
Question of the Week
CROI
RWHAP Clinical Conference
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
DEA-Compliant SUD Webinars
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
Did You Know?
FAQs
Fellow/Student Resources
Fellow/Student Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Mission
Scientific Leadership Board
Core Faculty
IAS-USA Award Recipients
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Practice Question of the Week
December 4, 2023: GLP-1RA Effects in Randomized Control Trials
Glucagon-like peptide-1 receptor antagonists (GLP-1RAs) have shown several potential off-target effects. Which of the following has been demonstrated in randomized control trials?
A. GLP-1RAs reduce adverse cardiovascular outcomes in obesity among those with known atherosclerotic cardiovascular disease (ASCVD)
B. GLP-1RAs reduce adverse cardiovascular outcomes in obesity among those with and without known ASCVD
C. GLP-1RAs decrease heart failure events among those with heart failure with preserved ejection fraction and with obesity
D. GLP-1RAs reduce the severity of substance use disorders
E. All of the above
Register for the Virtual Course
View Archived Questions
Leave Feedback
Subscribe
CLOSE